Evidence map›Paper›PMID 36241425›Full record

ArticleLife science alliance2023

Low expression of EXOSC2 protects against clinical COVID-19 and impedes SARS-CoV-2 replication.

Tobias Moll, Valerie Odon, Calum Harvey, Mark O Collins, Andrew Peden, John Franklin, Emily Graves, Jack Ng Marshall, Cleide Dos Santos Souza, Sai Zhang and 10 more

Open access · goldAbstract read
In one paragraph

Article in Life science alliance, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.3field-weighted citation impact, top 44% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

20 authors at 5 institutions in 2 countries.

Tobias MollSheffield Institute for Translational Neuroscience, University of Sheffield, Sheffield, UK.ORCID 0000-0001-5928-2514
Valerie OdonMedical Research Council Human Immunology Unit, Medical Research Council Weatherall Institute of Molecular Medicine, Radcliffe Department of Medicine, University of Oxford, Oxford, UK.
Calum HarveySheffield Institute for Translational Neuroscience, University of Sheffield, Sheffield, UK.
Mark O CollinsSchool of Biosciences, University of Sheffield, Sheffield, UK.ORCID 0000-0002-7656-4975
Andrew PedenSchool of Biosciences, University of Sheffield, Sheffield, UK.
John FranklinSheffield Institute for Translational Neuroscience, University of Sheffield, Sheffield, UK.
Emily GravesSheffield Institute for Translational Neuroscience, University of Sheffield, Sheffield, UK.
Jack Ng MarshallSheffield Institute for Translational Neuroscience, University of Sheffield, Sheffield, UK.
Cleide Dos Santos SouzaSheffield Institute for Translational Neuroscience, University of Sheffield, Sheffield, UK.
Sai ZhangDepartment of Genetics, Stanford University School of Medicine, Stanford, CA, USA.
Lydia CastelliSheffield Institute for Translational Neuroscience, University of Sheffield, Sheffield, UK.
Guillaume HautbergueSheffield Institute for Translational Neuroscience, University of Sheffield, Sheffield, UK.ORCID 0000-0002-1621-261X
Mimoun AzzouzSheffield Institute for Translational Neuroscience, University of Sheffield, Sheffield, UK.ORCID 0000-0001-6564-5967
David GordonDepartment of Cellular and Molecular Pharmacology, University of California San Francisco, San Francisco, CA, USA.
Nevan KroganDepartment of Cellular and Molecular Pharmacology, University of California San Francisco, San Francisco, CA, USA.ORCID 0000-0003-4902-337X
Laura FerraiuoloSheffield Institute for Translational Neuroscience, University of Sheffield, Sheffield, UK.ORCID 0000-0001-9118-5714
Michael P SnyderDepartment of Genetics, Stanford University School of Medicine, Stanford, CA, USA.
Pamela J ShawSheffield Institute for Translational Neuroscience, University of Sheffield, Sheffield, UK.
Jan RehwinkelMedical Research Council Human Immunology Unit, Medical Research Council Weatherall Institute of Molecular Medicine, Radcliffe Department of Medicine, University of Oxford, Oxford, UK.ORCID 0000-0003-3841-835X
Johnathan Cooper-KnockSheffield Institute for Translational Neuroscience, University of Sheffield, Sheffield, UK j.cooper-knock@sheffield.ac.uk.ORCID 0000-0002-0873-8689
University of Sheffield · GBStanford University · USUniversity of Oxford · GBGladstone Institutes · USUniversity of California, San Francisco · US

Funding

PRODUCTION CENTER FOR MAPPING REGULATORY REGIONS OF THE HUMAN GENOMEUM1HG009442 · NHGRI · STANFORD UNIVERSITY · PI SNYDER, MICHAEL P. · 2017 to 2021
$20.1M
Stanford Islet Research CoreP30DK116074 · NIDDK · STANFORD UNIVERSITY · PI Seung K Kim · 2017 to 2026
$19.5M
Signature Protein Profiles to Identify AAAsP50HL083800 · NHLBI · STANFORD UNIVERSITY · PI DALMAN, RONALD L · 2006 to 2010
$13.7M
DNA Variants and AAA DiseaseR01HL101388 · NHLBI · STANFORD UNIVERSITY · PI TSAO, PHILIP S · 2010 to 2013
$1.6M
MicroRNA Regulation of Nicotine Accelerated AAAsR01HL122939 · NHLBI · PALO ALTO VETERANS INSTIT FOR RESEARCH · PI TSAO, PHILIP S · 2014 to 2017
$1.4M
Ultra high throughput sequencer for sustaining and enhancing multi-scale genomic studiesS10OD025212 · OD · STANFORD UNIVERSITY · PI SNYDER, MICHAEL P. · 2018 to 2018
$600k
Biotechnology and Biological Sciences Research Council BB/S009566/1Department of Health IS-BRC-1215-20017Department of Health NF-SI-0617-10077Medical Research Council MC_UU_00008/8NHGRI NIH HHS UM1 HG009442NHLBI NIH HHS P50 HL083800NHLBI NIH HHS R01 HL101388NHLBI NIH HHS R01 HL122939NIDDK NIH HHS P30 DK116074NIH HHS S10 OD025212Wellcome TrustWellcome Trust 203141/Z/16/ZWellcome Trust 216596/Z/19/Z
6 · The paper itself

Abstract

New therapeutic targets are a valuable resource for treatment of SARS-CoV-2 viral infection. Genome-wide association studies have identified risk loci associated with COVID-19, but many loci are associated with comorbidities and are not specific to host-virus interactions. Here, we identify and experimentally validate a link between reduced expression of EXOSC2 and reduced SARS-CoV-2 replication. EXOSC2 was one of the 332 host proteins examined, all of which interact directly with SARS-CoV-2 proteins. Aggregating COVID-19 genome-wide association studies statistics for gene-specific eQTLs revealed an association between increased expression of

Indexed as

COVID-19SARS-CoV-2Chromatography, LiquidCodon, NonsenseDNA-Directed RNA PolymerasesExosome Multienzyme Ribonuclease ComplexGenome-Wide Association StudyHumansRNA-Binding ProteinsRNA, ViralTandem Mass SpectrometryViral Replicase Complex ProteinsVirus ReplicationCodon, NonsenseDNA-Directed RNA PolymerasesEXOSC2 protein, humanExosome Multienzyme Ribonuclease ComplexRNA-Binding ProteinsRNA, ViralViral Replicase Complex Proteins

Identifiers

PMID36241425
PMCPMC9585911
OpenAlexW4306194499

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.